Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer Journal Article


Authors: Shum, K. Y.; Kris, M. G.; Gralla, R. J.; Burke, M. T.; Marks, L. D.; Heelan, R. T.
Article Title: Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer
Abstract: 10-Ethyl-10-deaza-aminopterin (10-EDAM) is an analog of methotrexate that differs from its compound by modification of the N10 position and demonstrates greater preclinical antitumor activity and less toxicity. In this phase II trial, 20 patients with stage III or IV non-small-cell lung cancer (NSCLC) were administered 10-EDAM at a dose of 80 mg/m2 once weekly for 5 weeks. No patient had previously received chemotherapy. Nineteen of the 20 patients were adequately treated for response assessment. Six of 19 patients (32%) experienced a major objective response (exact 95% confidence limits, 15% to 55%). The median duration of response has not been reached and will exceed 13 months. Mucositis was the most common toxicity observed. Leukopenia was seen in only 10%, and 15% had platelet nadirs < 100,000/μL. At the dosage and schedule used, 10-EDAM is an active agent in patients with NSCLC who are previously untreated with chemotherapy with a predicted response rate ≥ 15% (P = .05). Because of its level of antitumor activity and the fact that 10-EDAM causes minimal myelosuppression, it is a suitable agent for further study in combination with other chemotherapeutic agents in this disease.
Keywords: clinical article; phase 2 clinical trial; leukopenia; lung non small cell cancer; mucosa inflammation; thrombocytopenia; lung cancer; age; rash; intravenous drug administration; edatrexate; human; male; female
Journal Title: Journal of Clinical Oncology
Volume: 6
Issue: 3
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1988-03-01
Start Page: 446
End Page: 450
Language: English
DOI: 10.1200/jco.1988.6.3.446
PUBMED: 2832548
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark Kris
    869 Kris
  2. Robert T Heelan
    140 Heelan
  3. Linda Marks
    10 Marks
  4. Richard J. Gralla
    69 Gralla